X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (325) 325
anti-dyskinesia agents - therapeutic use (234) 234
male (176) 176
female (173) 173
anti-dyskinesia agents - adverse effects (154) 154
botulinum toxins - therapeutic use (138) 138
middle aged (120) 120
adult (112) 112
index medicus (109) 109
clinical neurology (107) 107
anti-dyskinesia agents - administration & dosage (106) 106
botulinum toxins - adverse effects (99) 99
treatment outcome (97) 97
botulinum toxin (90) 90
aged (86) 86
botulinum toxins - administration & dosage (76) 76
neurosciences (66) 66
pharmacology & pharmacy (50) 50
double-blind (46) 46
animals (44) 44
dyskinesia, drug-induced - drug therapy (40) 40
psychiatry (39) 39
antipsychotic agents - adverse effects (37) 37
child (37) 37
injections (37) 37
adolescent (35) 35
cervical dystonia (35) 35
dystonia (35) 35
retrospective studies (34) 34
efficacy (33) 33
anti-dyskinesia agents - pharmacology (32) 32
dose-response relationship, drug (32) 32
haloperidol - adverse effects (31) 31
time factors (31) 31
injections, intramuscular (29) 29
botulinum toxins, type a - therapeutic use (28) 28
muscle spasticity - drug therapy (27) 27
aged, 80 and over (26) 26
haloperidol - therapeutic use (25) 25
safety (25) 25
dystonia - drug therapy (24) 24
follow-up studies (24) 24
botulinum toxins - pharmacology (23) 23
haloperidol (23) 23
severity of illness index (22) 22
surgery (22) 22
botulinum toxins, type a - adverse effects (21) 21
rehabilitation (20) 20
torticollis - drug therapy (20) 20
antipsychotic agents - therapeutic use (19) 19
drug therapy (19) 19
electromyography (19) 19
gastroenterology & hepatology (19) 19
management (19) 19
spasticity (19) 19
children (18) 18
medicine, general & internal (18) 18
movement disorders - drug therapy (18) 18
prospective studies (18) 18
tetrabenazine - therapeutic use (18) 18
trial (18) 18
care and treatment (17) 17
movement disorders (17) 17
tardive dyskinesia (17) 17
therapy (17) 17
double-blind method (16) 16
drug therapy, combination (16) 16
dyskinesia (16) 16
dyskinesia, drug-induced - etiology (16) 16
neurology (16) 16
research (16) 16
schizophrenia - drug therapy (16) 16
blepharospasm - drug therapy (15) 15
levodopa - adverse effects (15) 15
pediatrics (15) 15
randomized controlled trials as topic (15) 15
rats (15) 15
abridged index medicus (14) 14
achalasia (14) 14
botulinum toxins, type a (14) 14
child, preschool (14) 14
esophageal achalasia - therapy (14) 14
sialorrhea - drug therapy (14) 14
a toxin (13) 13
antiparkinson agents - adverse effects (13) 13
cerebral-palsy (13) 13
medicine & public health (13) 13
parkinson's disease (13) 13
risk factors (13) 13
schizophrenia (13) 13
drug administration schedule (12) 12
injection (12) 12
muscle spasticity - etiology (12) 12
ophthalmology (12) 12
parkinson disease - drug therapy (12) 12
spasmodic torticollis (12) 12
tardive-dyskinesia (12) 12
tetrabenazine (12) 12
benzodiazepines - therapeutic use (11) 11
botulinum toxins, type a - administration & dosage (11) 11
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (313) 313
German (8) 8
French (7) 7
Spanish (7) 7
Japanese (6) 6
Dutch (1) 1
Portuguese (1) 1
Russian (1) 1
Swedish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Drugs, ISSN 0012-6667, 2015, Volume 75, Issue 5, pp. 487 - 501
This narrative review reports on the pharmacological and pharmacokinetic properties of rotigotine, a non-ergolinic D-3/D-2/D-1 dopamine receptor agonist... 
PLASMA-LEVELS | SAFETY | DOUBLE-BLIND | PHARMACOLOGY & PHARMACY | TOXICOLOGY | PLACEBO-CONTROLLED TRIAL | QUALITY-OF-LIFE | CLINICAL-FEATURES | OPEN-LABEL EXTENSION | LONG-TERM TREATMENT | DOPAMINE AGONIST ROTIGOTINE | PATCH | Thiophenes - therapeutic use | Restless Legs Syndrome - epidemiology | Thiophenes - adverse effects | Humans | Dopamine Agonists - therapeutic use | Tetrahydronaphthalenes - therapeutic use | Dopamine Agonists - adverse effects | Parkinson Disease - drug therapy | Thiophenes - administration & dosage | Tetrahydronaphthalenes - adverse effects | Restless Legs Syndrome - metabolism | Antiparkinson Agents - therapeutic use | Restless Legs Syndrome - drug therapy | Drug Interactions | Tetrahydronaphthalenes - administration & dosage | Parkinson Disease - epidemiology | Anti-Dyskinesia Agents - administration & dosage | Parkinson Disease - metabolism | Comorbidity | Dopamine Agonists - pharmacokinetics | Tetrahydronaphthalenes - pharmacokinetics | Evidence-Based Medicine | Antiparkinson Agents - adverse effects | Transdermal Patch - adverse effects | Antiparkinson Agents - pharmacokinetics | Anti-Dyskinesia Agents - therapeutic use | Thiophenes - pharmacokinetics | Animals | Anti-Dyskinesia Agents - adverse effects | Dopamine Agonists - administration & dosage | Antiparkinson Agents - administration & dosage | Anti-Dyskinesia Agents - pharmacokinetics | Practice Guidelines as Topic
Journal Article
Journal Article
Cochrane database of systematic reviews (Online), ISSN 1469-493X, 2009, Issue 2, pp. CD006996 - CD006996
Journal Article
Psychopharmacology, ISSN 0033-3158, 10/2006, Volume 188, Issue 3, pp. 281 - 292
This double-blind, placebo-controlled study investigated the efficacy and safety of intramuscular (IM) aripiprazole and IM haloperidol for the treatment of... 
Intramuscular antipsychotic therapy | Acute agitation | Efficacy | Intramuscular aripiprazole | Safety | Intramuscular haloperidol | intramuscular aripiprazole | MANAGEMENT | PSYCHIATRY | NEUROSCIENCES | acute agitation | efficacy | ATYPICAL ANTIPSYCHOTICS | RELAPSE | safety | intramuscular antipsychotic therapy | PHARMACOLOGY & PHARMACY | OLANZAPINE | SHORT-TERM | ZIPRASIDONE | Piperazines - administration & dosage | Psychotic Disorders - complications | Antipsychotic Agents - adverse effects | Humans | Haloperidol - administration & dosage | Male | Schizophrenia - complications | Withholding Treatment - statistics & numerical data | Aripiprazole | Psychomotor Agitation - drug therapy | Quinolones - adverse effects | Time Factors | Antipsychotic Agents - therapeutic use | Quinolones - therapeutic use | Adult | Female | Anti-Dyskinesia Agents - administration & dosage | Drug Therapy, Combination | Basal Ganglia Diseases - chemically induced | Acute Disease | Double-Blind Method | Administration, Oral | Haloperidol - therapeutic use | Treatment Outcome | Piperazines - therapeutic use | Injections, Intramuscular | Haloperidol - adverse effects | Piperazines - adverse effects | Antipsychotic Agents - administration & dosage | Anti-Dyskinesia Agents - therapeutic use | Quinolones - administration & dosage | Anti-Dyskinesia Agents - adverse effects | Adolescent | Psychomotor Agitation - complications | Benzodiazepines - administration & dosage | Benzodiazepines - adverse effects | Psychotic Disorders - drug therapy | Schizophrenia - drug therapy | Blood Glucose - metabolism | Benzodiazepines - therapeutic use | Schizophrenia | Clinical trials | Comparative studies | Side effects | Pharmacology | Muscular system
Journal Article
Journal Article